[New antilipemics: prospects].
Farnier M.
Therapie. 2003 Jan-Feb;58(1):97-105. doi: 10.2515/therapie:2003014.
Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy.
Sanchez VA, Dinh PC Jr, Monahan PO, Althouse S, Rooker J, Sesso HD, Dolan ME, Weinzerl M, Feldman DR, Fung C, Einhorn LH, Frisina RD, Travis LB.
JAMA Oncol. 2024 Jul 1;10(7):912-922. doi: 10.1001/jamaoncol.2024.1233.
Flavonoids and metabolic syndrome.
Galleano M, Calabro V, Prince PD, Litterio MC, Piotrkowski B, Vazquez-Prieto MA, Miatello RM, Oteiza PI, Fraga CG.
Ann N Y Acad Sci. 2012 Jul;1259:87-94. doi: 10.1111/j.1749-6632.2012.06511.x.
Lipid Metabolism, Methylation Aberrant, and Osteoporosis: A Multi-omics Study Based on Mendelian Randomization.
Zhang Z, Duan Y, Huo J.
Calcif Tissue Int. 2024 Feb;114(2):147-156. doi: 10.1007/s00223-023-01160-6. Epub 2023 Dec 10.
Trends in epidemiology of dyslipidemias in India.
Sharma S, Gaur K, Gupta R.
Indian Heart J. 2024 Mar;76 Suppl 1(Suppl 1):S20-S28. doi: 10.1016/j.ihj.2023.11.266. Epub 2024 Feb 12.
Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study.
Tan Z, Hong J, Sun A, Ding M, Shen J.
Front Endocrinol (Lausanne). 2023 Dec 1;14:1301163. doi: 10.3389/fendo.2023.1301163. eCollection 2023.
The causal relationship between pure hypercholesterolemia and psoriasis: A bidirectional, two-sample Mendelian randomization study.
Bai R, Ren L, Guo J, Xian N, Luo R, Chang Y, Dai Y, Lei H, Zheng Y.
Skin Res Technol. 2023 Dec;29(12):e13533. doi: 10.1111/srt.13533.
Clinical pharmacokinetics of cerivastatin.
Mück W.
Clin Pharmacokinet. 2000 Aug;39(2):99-116. doi: 10.2165/00003088-200039020-00002.
Oxylanosterols as modifiers of cholesterol biosynthesis.
Trzaskos JM.
Prog Lipid Res. 1995;34(2):99-116. doi: 10.1016/0163-7827(94)00008-a.
Why Is Very High Cholesterol Content Beneficial for the Eye Lens but Negative for Other Organs?
Widomska J, Subczynski WK.
Nutrients. 2019 May 15;11(5):1083. doi: 10.3390/nu11051083.
